About $2 Million was Spent Advertising Invokana in Medical Journals in January 2014

by Client Services

It’s a new year, which means a variety of new products making big investments, advertising in print medical journals. Invokana, which ended 2013 as the top drug product advertised in medical journals, continues to be #1 on the list through January of this year. This product comprises about 5% of the total share among all drugs. Brintellix, an antidepressant from Takeda and Lundbeck, just launched late last year and now ranks second on the list. Fetzima is an SNRI from Forest.

Top 5 Print Ad Drugs (Dollars): Jan. 2014

#1 Invokana – $2 MM (N/A)

#2 Brintellix Tablets - $1 MM (N/A)

#3 Fetzima – $885,000 (N/A)

#4 Xarelto – $816,000 (-43%)

#5 Breo Ellipta Inhaler – $804,000 N/A)

The percentage changes compare January 2014 to that same time period in 2013. For more information on these ad insights or other data, let one of us know.

Kantar Media sets the standard for accurate, comprehensive competitive advertising intelligence in the professional healthcare arena. Check back next month for updated data on the top products, classes, companies and category movers year-to-date.